AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia

Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial

Hikal Q2 FY25 revenue stood at Rs. 453 Cr

In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%

Zydus Wellness Q2 FY25 sales up 12% at Rs. 490.7 Cr

Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore

Medanta to operate and manage 750 bed super speciality hospital in Pitampura, New Delhi

Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years

Max Healthcare posts Q2 FY25 consolidated PAT at Rs. 281.81 Cr

Max Healthcare Institute has reported total income of Rs. 1,748.30 crores during the period ended September 30, 2024

JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr

JB’s domestic business continued to out-perform the market with all our major brands posting strong growth

KIMS to acquire 3,000 beds in next 5 years in Kerala

The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode

Yatharth Hospitals acquires 60% stake in 400-bedded hospital in Faridabad for Rs. 91 Cr

PM Modi launches and inaugurates Rs. 12,850 crore health projects at AIIA, New Delhi

These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide

Sumitomo Corporation entered into contract with Revorf

Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies